 BetterLife Pharma Inc. revealed early positive in vitro results of its proprietary inhaled interferon alpha-2b product, AP-00, from a preclinical study at Dr Stephen Barrs Lab at the ImPaKT Facility, at the Schulich School of Medicine and Dentistry, in Western University, Ontario. The Vancouver, British Columbia-based biotechnology company said early data on its recombinant human interferon alpha-2b rhIFN2b, or AP-003 product shows potent anti-viral activity against the SARS-CoV-2 Delta variant up to 97 protection in human cells infected with the virus. 